[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571058":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":12,"centralContacts":22,"locations":31,"responsibleParty":106,"collaborators":12,"id":108,"slug":109,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":12,"eligibilityCriteria":114,"healthyVolunteers":110,"sex":115,"minAge":116,"maxAge":12,"enrollmentInfo":117,"targetDuration":12,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":34,"whyStopped":12,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},{"fullName":5,"class":6},"University of Southern Denmark","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Care","NO_INTERVENTION","Standard intravenous treatment in accordance with local or national procedures",null,{"label":14,"type":15,"description":14,"interventionNames":16},"Oral treatment","ACTIVE_COMPARATOR",[17],"Other: Oral treatment",[19],{"type":6,"name":14,"description":20,"armGroupLabels":21,"otherNames":12},"Patients randomized to oral treatment will commence the oral treatment immediately. The oral treatment is based on specially developed treatment suggestions developed by microbiologists and specialists in infectious diseases from the participating regions, and in respect with local treatment guidelines (detailed described in the protocol).",[14],[23,28],{"name":24,"role":25,"phone":26,"phoneExt":12,"email":27},"Mariana Bichuette Cartuliares","CONTACT","+45 79971113","mbc@rsyd.dk",{"name":29,"role":25,"phone":26,"phoneExt":12,"email":30},"Helene Skjøt-Arkil","hsa@rsyd.dk",[32,46,56,64,76,85,94],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":12},"Sygehus Sønderjylland","RECRUITING","Aabenraa","Southern Denmark","6200","Denmark","DK",{"type":41,"coordinates":42},"Point",[43,44],9.41741,55.04434,{"lat":44,"lon":43},{"facility":47,"status":48,"city":49,"state":12,"zip":50,"country":38,"countryCode":39,"cosmosGeoPoint":51,"geoPoint":55,"contacts":12},"Bispebjerg and Frederiksberg Hospital","ACTIVE_NOT_RECRUITING","Copenhagen","2400",{"type":41,"coordinates":52},[53,54],12.56553,55.67594,{"lat":54,"lon":53},{"facility":57,"status":34,"city":49,"state":12,"zip":12,"country":38,"countryCode":39,"cosmosGeoPoint":58,"geoPoint":60,"contacts":61},"Nordsjællands Hospital",{"type":41,"coordinates":59},[53,54],{"lat":54,"lon":53},[62],{"name":63,"role":25,"phone":12,"phoneExt":12,"email":12},"Jon Gitz Holler",{"facility":65,"status":34,"city":66,"state":12,"zip":67,"country":38,"countryCode":39,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Esbjerg and Grindsted Sygehus","Esbjerg","6700",{"type":41,"coordinates":69},[70,71],8.45187,55.47028,{"lat":71,"lon":70},[74],{"name":75,"role":25,"phone":12,"phoneExt":12,"email":12},"Peter Biesenbach",{"facility":77,"status":48,"city":78,"state":12,"zip":79,"country":38,"countryCode":39,"cosmosGeoPoint":80,"geoPoint":84,"contacts":12},"Herlev and Gentofte Hospital","Herlev","2730",{"type":41,"coordinates":81},[82,83],12.43998,55.72366,{"lat":83,"lon":82},{"facility":86,"status":48,"city":87,"state":12,"zip":88,"country":38,"countryCode":39,"cosmosGeoPoint":89,"geoPoint":93,"contacts":12},"Amager and Hvidovre Hospital","Hvidovre","2650",{"type":41,"coordinates":90},[91,92],12.47708,55.64297,{"lat":92,"lon":91},{"facility":95,"status":34,"city":96,"state":12,"zip":97,"country":38,"countryCode":39,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Sygehus Lillebælt","Kolding","6000",{"type":41,"coordinates":99},[100,101],9.47216,55.4904,{"lat":101,"lon":100},[104],{"name":105,"role":25,"phone":12,"phoneExt":12,"email":12},"Lone Wulff Madsen",{"type":107,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100571058","intravenous-versus-oral-treatment-of-the-main-acute-infections-100571058",false,"NCT06715306","Intravenous Versus Oral Treatment of the Main Acute Infections","Intravenous Versus Oral Treatment of the Main Acute Infections in Emergency Departments","Inclusion Criteria:\n\n* Suspected respiratory tract infection, urinary tract infection, or cellulitis by the attending physician\n* Planned or initiated intravenous antibiotic treatment\n\nExclusion Criteria:\n\n* if received more than two doses of intravenous antibiotics;\n* systolic blood pressure \\\u003C90 mmHg;\n* nausea and\u002For vomiting in more than one short-term instance during the last 2 days;\n* suspected significantly reduced gastrointestinal absorption;\n* confirmed plasma-lactate \\> 2;\n* pregnant or nursing;\n* unable to give informed consent;\n* severe immunodeficiency;\n* urgent vital treatment needed.","ALL","18 Years",{"count":118,"type":119},4000,"ESTIMATED","INTERVENTIONAL",[122],"NA","Patients admitted to the hospital with acute infections are often treated with intravenous (IV) antibiotics. Around 70% of these infections fall into three categories: respiratory tract infections, urinary tract infections, and cellulitis. A Danish study found that 76% of patients admitted with suspected community-acquired pneumonia and treated with antibiotics received them intravenously. Based on an extrapolated estimate from an unpublished local survey, approximately 50,000 patients in Denmark are admitted each year for infections and treated with IV antibiotics. The average hospital stay for these patients is 5.9 days, resulting in a total of 295,000 hospital days annually, accounting for about 7% of total hospital admissions in Denmark. This represents an annual cost of 2.3 billion DKK. While some patients need hospitalization due to their overall health or other serious conditions, others remain hospitalized primarily to receive IV antibiotics.\n\nExpanding the use of oral antibiotics in emergency departments should be pursued only if it can demonstrate comparable efficacy and safety to IV administration. Therefore this study will investigate the efficiency of primarily oral antibiotics in acutely admitted patients with proven or suspected infections. Additionally, the investigators will evaluate the safety of oral regimen for these patients.",[125,126,127],"Respiratory Tract Infections","Urinary Tract Infections","Cellulitis",[129,130,131],"Oral antibiotic therapy","intravenous antibiotic therapy","intravenous-to-oral-switch","2026-03-03",{"date":134,"type":135},"2026-03-05","ACTUAL",{"date":137,"type":135},"2025-01-15",{"date":139,"type":119},"2028-01-06",{"name":5,"class":6},7]